How Common Is Detransition? Rates, Follow-Up and Unknowns

How often people detransition or stop treatment: every major estimate, what it measured, the time lag, and why loss to follow-up leaves the true rate unknown.

Overview

"How many people detransition?" sounds like a question with one answer. It isn't. Published figures run from under 0.1% to around 30%, and almost all of them are honest numbers. They differ because each study counted something different, in a different group of people, over a different length of time, and then lost track of a different share of them.

This page sets out every major published estimate of detransition (stopping or reversing a transition), discontinuation (stopping a treatment, for any reason) and regret (the feeling that transition was a mistake). For each one it asks four questions: who was studied, what was actually counted, how long people were followed, and how many dropped out of sight. It then looks at the time lag before detransition, at why loss to follow-up makes the true rate unknown, and at the gap between the often-repeated "about 1%" and detransitioners' own accounts of leaving their clinics without a word.

Definitions and reasons are covered on the detransition overview, the origin of the "1% regret" figure on transition regret, children who stop before any medical step on desistance, returns to transition on retransition, and national reviews on evidence reviews. This page collects the numbers in one place.

No study has followed a representative group of today's patients for long enough, with few enough people lost, to give a reliable detransition rate. Every published figure is either a minimum (it counts only the cases a clinic or registry happened to see) or a description of a self-selected sample. The honest summary, shared by researchers on both sides of the debate, is that the rate is unknown (Cohn 2023; Feigerlova 2025).

Three different things being counted

Before comparing numbers, it helps to see that studies are measuring at least three different events. They overlap, but they are not the same.

  • Discontinuation means a treatment stopped. In records studies this usually means no new hormone prescription for a set period (90 days in one US study, a missing prescription on a single date in a Dutch one). It includes people who stopped because of side effects, cost, losing insurance, reaching their goals, or buying hormones elsewhere, as well as people who detransitioned.
  • Detransition means a person stopped or reversed transition, often (but not always) because they no longer identify as trans. Studies define it in many ways: switching to hormones of one's own sex, a clinician's note, a legal change back, or a survey answer such as "ever gone back to living as your sex assigned at birth, at least for a while".
  • Regret is a judgement about the past. It can exist without detransition (someone who stays because reversal seems impossible) and detransition can happen without it. Regret is measured by questionnaires, by requests for reversal surgery, or by what happens to be written in case notes.

Two further choices matter as much: the denominator (everyone referred, everyone who started hormones, everyone who had one surgery, or everyone who answered a survey) and the observation window (how long after treatment people were watched). Figures built on different choices cannot be averaged.

Summary table

The table lists the main published estimates. "Follow-up" is the approximate time people were observed after the relevant treatment; "lost" is the share who dropped out of sight where the study reports it. Each study is discussed in the sections below.

StudyPopulationWhat was measuredFollow-upRate
de Vries et al. 2011 (Amsterdam)70 screened adolescents on puberty blockers, 2000–2008Stopping blockers before cross-sex hormonesUntil hormones began (about 2 years)0 of 70 stopped; all went on to hormones
Brik et al. 2020 (Leiden)143 adolescents who started blockers, 2010–2018No longer wanting gender treatment while on blockersUntil hormones or mid-20193.5% (5 of 143); 6% stopped blockers for any reason
van der Loos et al. 2022 (Amsterdam)720 people who started blockers and then hormones as adolescentsNo hormone prescription in the national register at end of 2018Short; median age at follow-up about 19–202% (16 of 720) had no prescription
Wiepjes et al. 2018 (Amsterdam)Adults who had testes or ovaries removed, 1972–2015Clinic-recorded regret: restarting hormones of own sex after gonadectomyTypical follow-up about 6 years; 36% stopped attending0.6% of males, 0.3% of females (14 people)
Carmichael et al. 2021 (UK GIDS)44 selected 12–15-year-olds on blockers, 2011–2015Going on to cross-sex hormonesUp to 3 years; 14 still in data at 3 years43 of 44 (98%) went on to hormones
Butler et al. 2022 (UK GIDS endocrine clinics)1,089 young people with known outcomes at discharge, 2008–2021Ceasing to identify as trans before discharge to adult careUntil discharge (late teens)8.3% overall; 5.3% stopped blockers or hormones and reverted
Davies et al. 2019 (UK adult clinic; conference abstract)3,398 active adult patients over one yearKeywords for regret or detransition in recordsUnknown0.47% (16 people)
Hall et al. 2021 (UK adult clinic)175 adults discharged in one yearCase notes meeting the authors' definition of detransitionData ended 16 months after last discharge; 22% stopped attending6.9% (12 people)
Boyd et al. 2022 (one English GP practice)41 patients who had started hormonesChoosing to stop hormones; notes of detransition or regret17 months to 10 years on treatment20% stopped (8); 5 of them with detransition or regret noted
Roberts et al. 2022 (US military health system)952 adolescents and adults on hormonesNo new prescription for more than 90 daysUp to 4 yearsAbout 30% stopped; 36% of females, 19% of males
Dhejne et al. 2014 (Sweden)681 people granted legal change plus surgery, 1960–2010Application to reverse legal genderUp to 50 years; recent decade incomplete2.2% (15 people)
Clark et al. 2025 (Sweden)2,467 adults who changed legal gender, 2013–2023Changing legal gender backAbout 5 years from diagnosis on average0.9% (21 people)
Kaltiala et al. 2024 (Finland)1,359 people who had hormonal transition, 1996–2019Discontinuing established hormone treatment (national registers)8.5 years on average7.9%; risk about 2.7 times higher in 2013–2019 entrants
Nyquist et al. 2025 (Norway; retracted 2026)783 referred young people who started hormonesStopping hormones, as known to the clinicAbout 3 to over 20 years2.3% (18 people, all female)
Boskey et al. 2025 (Boston Children's Hospital)1,050 adolescents on hormones for 6+ months, 2007–2022Stopping hormones without restarting, per clinic recordsAbout 2.7 years on average; 210 not seen for over a year4% stopped; 0.5% re-identified with birth sex
Tang et al. 2022 (Kaiser Permanente)209 adolescents after mastectomyRegret noted in surgical or mental health recordsAbout 2 yearsAbout 1% (2 people)
Bruce et al. 2023 (Michigan)139 of 235 adults after mastectomyDecision Regret Scale (questionnaire)Median 3.6 years; 41% did not replyMedian regret score 0; 13 high-regret answers excluded
Bustos et al. 2021 (meta-analysis)7,928 surgery patients in 27 studiesRegret after any gender surgery, by each study's own measureUnder 1 year to 9 yearsAbout 1% pooled
Feigerlova 2025 (systematic review)15 studies, 3,804 minors and 3,270 adultsDiscontinuation at each stageMostly short or unreported1.6–9.8% stopped hormones in most studies; about 30% in one
Narayan et al. 2021 (surgeon survey)46 surgeons' recall of their patientsPatients who regretted or asked for reversalNot definedAbout 0.2–0.3%
Turban et al. 2021 / US Transgender Survey 201517,151 currently trans-identified adults who had transitioned in any wayEver "went back to living as your sex assigned at birth, at least for a while"Lifetime, self-reported13% ever (8% in the original report); 0.4% because transition "was not for them"
US Transgender Survey 202264,843 currently trans-identified respondentsSame questionLifetime, self-reported9% ever; 0.36% of those who medically transitioned because transition "was not for them"
Bachmann et al. 2024 (German insurance data)7,885 people aged 5–24 with a gender identity diagnosis in 2017Diagnosis still coded five years later5 years36.4% still had the diagnosis; 27.3% of girls aged 15–19

The detransitioner surveys (Littman 2021; Vandenbussche 2022; Littman et al. 2024; the DARE study, Rackliff et al. 2025) are not in the table because they recruit detransitioners and so cannot give a rate. They matter for a different reason: they show how many detransitioners never told their clinic, and how long detransition takes. Both points are covered below.

Clinic cohorts

Clinic studies follow people who were treated at one service. Their strength is that diagnoses and treatments are recorded. Their weakness is that the clinic only knows what patients come back to tell it.

The Dutch clinics

The Dutch protocol, developed in Amsterdam from the late 1990s, was the model for youth gender medicine worldwide: careful assessment, puberty blockers from about age 12, cross-sex hormones from about 16. Its studies give some of the lowest figures, and they are often quoted as evidence that young people rarely change course.

In the first Dutch blocker study, none of 70 screened adolescents stopped blockers, and all went on to cross-sex hormones (de Vries et al. 2011). At the Leiden clinic, 125 of 143 adolescents who started blockers (87%) went on to hormones, 9 (6%) stopped blockers, and 5 (3.5%) no longer wanted gender treatment (Brik et al. 2020). In the largest youth cohort, 704 of 720 people who started blockers and then hormones as adolescents (98%) still had a hormone prescription at the end of 2018 (van der Loos et al. 2022).

These are strong continuation figures for a narrow question. All three studies ended when hormones started or in the late teens and early twenties (median age about 19–20 in van der Loos). A register prescription shows hormones were paid for, not wanted. And people whose testes or ovaries have been removed need some sex hormone for life, so their prescriptions say little about whether they still support their transition. Detransitioners in that position describe exactly this:

I completely regret the hysterectomy. It was an elective surgery that I didn't need, and I have now to buy and use synthetic hormones for the rest of my life as my ovaries were also removed in the process. —riprovevole, detrans female

The Amsterdam adult data show why the window matters. Wiepjes et al. 2018 reviewed 6,793 people seen at the clinic between 1972 and 2015. Among adults who had their testes or ovaries removed, regret, defined as starting hormones of one's own sex afterwards, was recorded in 0.6% of males and 0.3% of females. This is the main source of the "under 1%" figure. But regret in this cohort appeared on average about 11 years after starting hormones (range roughly 4 to 22), while typical follow-up was about six years, and 36% of patients had stopped attending the clinic. Thirteen of the 14 regret cases had started hormones before 1998. The study's own data say that later patients had not yet been watched long enough for regret to show. The origin and misuse of this figure are covered in depth on transition regret.

UK children's service (GIDS)

England's Gender Identity Development Service (GIDS) at the Tavistock referred young people to two paediatric endocrine clinics for blockers and hormones. Its early blocker study followed 44 carefully selected 12–15-year-olds: 43 of 44 (98%) went on to cross-sex hormones, though only 14 were still in the data at three years (Carmichael et al. 2021).

The largest UK youth figure comes from the endocrine clinics' discharge records (Butler et al. 2022). Of 1,089 young people with known outcomes, 999 (91.7%) still identified as trans or gender diverse at discharge, and 90 (8.3%) did not. Of those 90, 32 stopped identifying as trans after their first appointment and before any medication, and 58 (5.3%) stopped blockers or hormones and returned to living as their sex. Stopping was more common among those referred before age 16 (9.2%) than those referred later (4.4%). Another 51 young people discharged themselves and 11 emigrated; their outcomes are unknown.

This is a better figure than many, because it covers a whole national service. But it ends at the moment of discharge, usually in the late teens, when young people were handed on to adult clinics. Anything that happened afterwards is invisible to it. One detransitioned man who went through the children's service described how that looks from the inside:

There's also the fact that the children's service wouldn't have any patient data for anyone once they pass age 18, so anyone who desisted beyond that age would not show it in the search either. It was the clinic I went to and anyone looking up my records there would find that I was discharged happy in my transition progress and a referral to adult services. As far as they're aware I'm still trans and I'll be in that research data as part of the 99% of "persisters". —cagedbunny83, detrans male

The Cass Review tried to close this gap with a data linkage study that would follow GIDS patients into adult services. Most adult clinics initially refused to share data, so the Review was published without it (see evidence reviews).

UK adult clinics

Two UK adult clinic figures are often quoted together, and they sit an order of magnitude apart.

The first, a conference abstract by Davies and colleagues (2019), searched one year of electronic records for 3,398 active patients at a national adult clinic for words related to regret or detransition, then reviewed the matches. It found 16 cases (0.47%). As Cohn 2023 notes, the follow-up time and loss to follow-up are unknown, and the sample was, by design, people still attending the clinic. Someone who had stopped coming could not appear in it. The abstract has never been published as a peer-reviewed paper.

The second, Hall et al. 2021, read the full case notes of 175 adults discharged from a different national clinic over one year. Twelve (6.9%) met the authors' definition of detransition, and regret was recorded in only two of them. More than a fifth (21.7%) had simply stopped attending. Data collection ended just 16 months after the last discharge, while the authors note that detransition is usually reported years after transition, so they describe 6.9% as probably too low. They concluded that detransition "might be more frequent than previously reported".

The contrast shows how method drives the answer: a keyword search of active patients finds less than a full read of discharged patients' notes, and both miss everyone who left without saying why.

Nordic registers

The Nordic countries can link national registers, which makes them less dependent on what any single clinic hears.

In Sweden, Dhejne et al. 2014 counted applications to reverse a legal gender change among 681 people who had legal change plus surgery between 1960 and 2010: 15 (2.2%). Applications came on average 7.5 to 8.5 years after the original change, so the apparent fall to 0.3% in the last decade is largely an artefact of too little time. A newer Swedish study of 2,467 adults who changed legal gender between 2013 and 2023 found 21 (0.9%) changed back (Clark et al. 2025). The authors call this a minimum: reversal needs a new application and assessment, and some detransitioners keep their documents for practical reasons. (The paper's discussion gives 0.09%, ten times lower than its own results.)

In Finland, Kaltiala et al. 2024 used national registers to follow 1,359 people who had hormonal transition between 1996 and 2019. Over an average of 8.5 years, 7.9% discontinued established hormone treatment. People who entered gender services between 2013 and 2019 were about 2.7 times as likely to stop as those who entered between 1996 and 2005, and they stopped sooner. The authors suggest the threshold for starting treatment may have fallen. This is the longest-running whole-country hormone figure available, and it is roughly eight times the Dutch youth figure.

A Norwegian national cohort of 1,258 referred young people recorded 18 people (2.3% of those who started hormones) who stopped, all of them female and all starting testosterone between 2015 and 2021 (Nyquist et al. 2025). The authors called it a minimum because many patients were not followed after discharge. The paper was retracted in 2026 for lacking ethics approval, not for errors in the data, so its numbers should be treated with extra caution.

US clinics

US clinic studies of adolescents give low figures over short windows. At Boston Children's Hospital, 973 of 1,050 adolescents who had been on hormones for at least six months (93%) were recorded as still taking them, 37 (4%) had stopped without restarting, and 5 (0.5%) had stopped because they again identified with their birth sex (Boskey et al. 2025). Average follow-up was about 2.7 years. And 210 of the 973 counted as continuing had not been seen for more than a year, with no record of moving to another provider. They were counted as continuing because nothing said otherwise.

As an illustration (not a finding of the study): if all 210 had in fact stopped, continuation would fall from 93% to about 73%. The truth is almost certainly somewhere in between, and the study cannot say where.

Surgical studies are similar. At Kaiser Permanente Northern California, regret was found in the records of 2 of 209 adolescents after mastectomy (about 1%), with typical follow-up of about two years and no one directly asked (Tang et al. 2022). In a Michigan survey of adults after mastectomy, the median regret score was zero, but 41% of eligible patients did not reply, non-repliers had been out of surgery longer, and 13 people who gave very high regret scores were excluded as presumed errors (Bruce et al. 2023).

Prescription and insurance data

Pharmacy and insurance records avoid one problem of clinic studies: they record whether prescriptions keep being filled, whether or not the patient goes back to the clinic. They bring a different problem: they cannot tell why someone stopped.

The US military health system

Roberts et al. 2022 followed 952 adolescents and adults in the US military health system (mostly children and spouses of service members, average age about 19) after they started hormones. Stopping was defined as no new prescription for more than 90 days after the last supply ran out, while the person was still using other military health care. After four years an estimated 70% were still filling prescriptions, so about 30% had stopped. Females taking testosterone were about 2.4 times as likely to stop as males taking oestrogen (36% against 19%), and people who started as adults were more likely to stop than those who started as minors.

This is the highest figure in the clinical literature, and it does not show that detransition is common. No reasons were recorded: stopping could mean detransition, side effects, cost, moving, or private hormones, and a 90-day gap counts short breaks. Equally, people who left military insurance vanish from the data, and anyone who no longer wanted to transition but kept filling prescriptions counts as continuing. In a commentary in the same journal, endocrinologist Michael Irwig argued that the figure, together with the shift towards consent-based prescribing and female patients, means older low rates may not apply to today's patients (Irwig 2022).

One detransitioned man described a path that a refill study would struggle to classify:

I was in that window when I wondered if I should have transitioned, but it was around 5 years before I started to seriously consider detransition and around 7 years when I stopped the hormones. I also switched to bio sex hormones at about the 8 year mark. Would that be a continuation in this study? —Educational-Fish-637, detrans male

Primary care

At one English GP practice, 8 of 41 patients who had started hormones (20%) chose to stop, on average after about five years; four had notes describing detransition and one recorded regret after removal of the testes (Boyd et al. 2022). The numbers are tiny, but a GP may be the only doctor who ever hears about a detransition.

Diagnosis persistence

German insurance data offer a different angle. Of 7,885 people aged 5 to 24 who had a gender identity diagnosis in 2017, only 36.4% still had it coded five years later, and the figure was lowest (27.3%) among girls aged 15 to 19 (Bachmann et al. 2024). This does not measure detransition: a dropped code can mean someone stopped seeing doctors, finished treatment, was coded differently, or moved to care outside the data. What it does show is that a gender identity diagnosis in a young person is far less stable over five years than the clinic continuation figures imply. How childhood gender dysphoria resolves without treatment is covered on desistance.

Surveys

Surveys ask people directly, which is the only way to learn their reasons. But a survey can only reach people who see it and want to answer, and that decides what it can find.

Surveys of trans-identified people

The US Transgender Survey is the largest survey of trans people in the world, recruited through trans community organisations. In 2015, 8% of respondents said they had ever "de-transitioned", defined as going back to living as their birth sex "at least for a while", and 62% of those were living as trans again at the time of the survey (James et al. 2016). Only 5% of those who had detransitioned said they did so because transition was not for them: 0.4% of the whole sample. A re-analysis found that 13% of respondents who had ever transitioned in any way had ever detransitioned, and 83% of them gave at least one external reason such as family pressure or stigma (Turban et al. 2021). In the 2022 survey, 9% had ever gone back to living as their birth sex, 82% of them for social and structural reasons, and only 0.36% of all respondents who had medically transitioned had done so because transition was not for them (USTS 2022).

These figures accurately describe their samples, and show that external pressure forces some trans people to stop. But both surveys only included people who identified as trans at the time, so anyone who stopped because they no longer believe they are trans had left the population being surveyed. The 0.36% figure is therefore a count of people who regret transition and still identify as trans — a group that will always be small. The authors of the 2021 re-analysis acknowledge this limitation, and the surveys' broad definition (any period of living as one's birth sex, including briefly when visiting family) also mixes very different experiences. Detransitioners point this out often:

This was NOT a study on detransitioners. This was a study on retransitioners or people who currently identify as trans who had detransitioned in the past. —Sorry-not-Sorry-666, desisted female

Surveys of detransitioners

Surveys recruited through detransition communities have the opposite bias. They reach people who now reject a trans identity, often with strong negative experiences, and miss those who detransitioned quietly or still identify as trans. They cannot give a rate, and their authors say so. Their value for this page lies in two findings that no clinic study can make.

First, most respondents had not told their clinic. Only 24% of Littman 2021's 100 detransitioners had told the clinicians who helped them transition, and only 27.1% of the 78 young adults in Littman et al. 2024. The Finnish authors of a clinic study of detransitioners cite similar figures, 24% to 29% (Kettula et al. 2025). Second, they show how long it takes: on average 3.9 years living transitioned in Littman 2021, and about five years identifying as trans in Littman et al. 2024.

The largest detransition survey, the DARE study of 957 people in the US and Canada, used a deliberately broad definition that included people who still identify as trans. In that sample, 42% had stopped and later restarted a transition (Rackliff et al. 2025), and one group of about 28%, more often trans women, had stopped involuntarily because of discrimination, family rejection or lost access to care (MacKinnon et al. 2025). So "detransition" in one survey and in another can describe largely different people. What happens to those who return to transition is covered on retransition.

Reviews and pooled estimates

Two systematic reviews pull these numbers together, and they reach very different headlines.

Bustos et al. 2021 pooled 27 studies of 7,928 surgery patients and estimated regret at about 1%. It is the most widely cited source for the "1%" figure. But follow-up in the included studies ran from under one year to about nine, almost all used home-made regret questions, and the largest single study (Wiepjes 2018, about half the patients) had lost track of 36%. Using an eight-year minimum follow-up and at least 85% retention, Cohn 2023 found that none of the 27 studies qualified.

Feigerlova 2025 reviewed 15 studies of hormonal treatment covering 3,804 minors and 3,270 adults. Before treatment, 0.8% to 7.4% changed their request; 1% to 7.6% stopped blockers; and 1.6% to 9.8% stopped hormones. The one US military study reported about 30% (19% of males, 35.6% of females), which falls outside the headline range. Definitions ranged from re-identifying with one's sex to a 90-day gap in prescriptions, 14 of the 15 studies looked back at old records, and the evidence was rated very low quality. The author's conclusion is that detransition "has been insufficiently investigated".

A surgeon survey is also quoted: 46 surgeons recalled 62 patients with regret among roughly 18,000 to 27,000 operations, about 0.2–0.3%, but only 30% of those invited replied and the authors say such surveys cannot measure prevalence (Narayan et al. 2021).

The time lag

Detransition and regret are slow. Every source that reports timing finds a delay of several years, and the longest-running data find the longest delays.

SourceGroupTime to detransition or regret
Littman 2021100 detransitioners (survey)3.9 years living transitioned on average (3.2 for females, 5.4 for males)
Littman et al. 202478 young adults (survey)About 5 years identifying as trans
Boyd et al. 20228 who stopped hormones (GP records)About 5 years on hormones on average
Kettula et al. 20259 Finnish adult detransitionersAbout 7 years on average (5 for those assessed after 2010)
Dhejne et al. 201415 Swedish legal reversals7.5 years (females) to 8.5 years (males) after legal change
Wiepjes et al. 201814 Dutch adults with recorded regretAbout 11 years after starting hormones (range 4–22)

Set against this, the follow-up in the studies with the lowest figures is short: about two years for the Kaiser mastectomy study, 2.7 years for the Boston cohort, the late teens for GIDS discharge, and 16 months after discharge for the UK adult clinic. A study that ends before the typical delay has passed cannot see most of what it is trying to measure. In a BMJ analysis, detransition researchers from a trans-affirming position made the same point: one to two years of follow-up is too short, and studies should run for five to ten (MacKinnon et al. 2023).

The time lag also interacts with when people were treated. Youth referrals rose steeply in the 2010s; in the US military data, 58% of patients had their first gender-related visit in the last 22 months of the study (Roberts et al. 2022). If detransition takes five to ten years, the people treated during the peak are only now reaching the period when it would show. The Finnish finding that later cohorts stop more, and sooner, is an early sign that the picture is still changing (Kaltiala et al. 2024).

Detransitioners describe that delay in their own timelines:

I was on T for 7 years. I understood my "mistake" at my 25th birthday. My 18th birthday was the day I took my first testosterone's shot. —manouxoxo, detrans female

5 years is nothing. It's been 12 years since I came out to my partner, children and close friends as what would be called non-binary today. It wasn't until I realised I'd always still have a female body on some level and that superficially changing it wasn't going to help me that I started to doubt and question. —Luck_Unlucky2, desisted female

Many describe an early "honeymoon" of relief before doubt sets in, which is one reason short studies look so reassuring. The psychology of that delay is covered on transition regret.

Loss to follow-up: why the true rate is unknown

Loss to follow-up means that people in a study stop being observed: they stop attending, move away, change insurer, or do not answer. In gender medicine it is common. Wiepjes lost 36%; Hall found 21.7% had stopped attending; Bruce had 41% non-response; Boskey had 210 people not seen for over a year. A BMJ analysis warns that more than 30% of patients drop out of some gender care studies (MacKinnon et al. 2023).

Loss to follow-up would matter less if the people lost were like the people who stayed. In this field there are good reasons to think they are not.

Detransitioners rarely tell the clinic

The survey evidence is consistent: roughly one in four detransitioners told the clinicians who treated them (Littman 2021; Littman et al. 2024). If that proportion held in a clinic cohort, a clinic that recorded every detransition it heard about would still see only about a quarter of them. This is a rough illustration, since the surveys are self-selected and the proportion is uncertain, but the direction of the bias is clear.

On r/detrans the reasons for not telling come up again and again. Some simply stopped and moved on:

Absolutely not. There is no record at the clinic I went to of me detransitioning so how would they know? The statistics are wildly inaccurate —frecklesownsmysoul, detrans female

I think the percentage is much higher, I'm a statistic and I didn't tell my doctors etc. I just stopped taking the hrt from the virtual appointments I had. —FormalSpinach6930, detrans female

Others expected not to be believed, or not to be welcome:

I didn't tell either clinic that treated me. I may be wrong but my sense is both doctors saw their client population as unstable and I feel that telling them won't be taken to heart for this reason. —rose_creek, detrans female

And some noticed that nobody asked:

I didn't even tell my doctor I just stopped going in and they never even cared to call or anything :) doctors don't care about us really —ek8422, detrans female

In a Canadian interview study of 28 people who stopped or reversed transition, many stopped hormones abruptly and clinics rarely followed up (MacKinnon et al. 2022). In the DARE sample, 43% said their health provider never seemed to know about detransition (Rackliff et al. 2025).

When people do tell, it may not be recorded

Telling the clinic is not the same as being counted. Some detransitioners describe files that were closed rather than updated, or a clinic that would not accept the word:

quite a bit of us have reached out to our gender therapists as well as endocrinologists who prescribed us HRT only to find out they closed our medical files and will not update them with the fact we medically detransitioned. —DetransIS, detrans female

One woman who was enrolled in a European study described being dropped by the clinic after raising doubts:

And of course they simply never contacted me for the follow up of the study I was in. That's one way to get a low regret rate for the treatment you built your whole career on I guess! —Crocheted-tiger, detrans female

These accounts cannot be counted, and they come from a self-selected forum. But they explain how a clinic can truthfully report that almost none of its patients detransitioned: the cases happened, and never entered the record. In Hall et al. 2021, regret was recorded for only 2 of the 12 detransitioners, and in Feigerlova 2025's review, the reason for stopping was unknown for 10 of 12 people in one UK clinic study.

How the lost are counted

Most cohort studies have to decide what to do with people they can no longer see, and the usual choice is to leave them in the "continuing" or "no regret" group, or to drop them. The Boston study counted 210 unseen patients as still on hormones. The Wiepjes regret figure was calculated over everyone who had gonadectomy, including those who had stopped attending. GIDS discharge figures end when young people are passed to adult care. In each case the lost are treated, explicitly or by default, as people for whom nothing went wrong.

There is a fair point on the other side. Treating every lost patient as a possible detransitioner gives an equally unrealistic upper bound, and Cohn 2023 has been criticised for scrutinising clinic studies more closely than the detransitioner surveys he relies on. Lost patients include people who moved, went private, or are doing well. The honest position is not that the lost are mostly detransitioners, but that nobody knows what proportion they are, and that the published rates assume, without evidence, that it is close to zero.

The record shows hormones, not identity

Prescription and register studies have a mirror-image problem. They can see a person stop hormones, but not why, and they cannot see a person who still takes hormones but no longer wants to. People who have had their testes or ovaries removed need some sex hormone for life, and some detransitioners keep taking cross-sex hormones for a period because switching is difficult, because they lack medical support, or because reversing the visible changes feels impossible. Others obtain hormones outside the system altogether (see DIY hormones). Errors can run in both directions, which is why prescription data cannot settle the question either way.

The "about 1%" claim and the clinic that never heard

The trans view

The figure most often repeated in trans communities is that detransition or regret affects about 1% of people, or fewer, and that most of those who stop do so because of outside pressure. In its strongest form, this view rests on real data: the largest surveys of trans people find that only a fraction of one percent stopped because transition was not right for them, the largest surgical meta-analysis finds about 1% regret, and the Dutch youth cohort finds 98% continuing.

Detransitioners who realise they aren't trans represent a tiny fraction of those who transition. [The largest survey of people who have accessed gender affirming care found a rate of around 0.36%] ... The rate that detransition at any point for any reason is 9%, but the vast majority are for external reasons as is listed in the report I linked. —curedheronthesabbath, trans woman (MTF)

Trans commenters also make a methodological point that is fair: broad definitions inflate the numbers in the other direction, by counting brief breaks and forced stops as if they were changes of mind.

If a trans woman has to skip a week of HRT because a demagogue canceled her insurance coverage, they count her as a detransitioner. If I go off hormones for a few months while I make preparations to flee my home, they count me as a detransitioner. —lukenbones, trans woman (MTF)

That criticism applies with real force to the 30% military figure and to the broad survey questions, and detransitioners should not treat any discontinuation figure as a detransition rate. Some trans commenters also hold both views at once, defending the low figure while insisting that the people inside it be heard:

The rate seems to be a bit lower than 1% from the few studies existing. Which is less than the majority of surgeries. However, it's really important to listen to those 1%. —GuerandeSaltLord, trans woman (MTF)

The detransitioner view

Detransitioners do not usually dispute that the 1% studies counted what they counted. They dispute that those studies could have counted them. The low figures come from places a detransitioner is least likely to be: an active clinic caseload, a survey of people who still identify as trans, a surgical follow-up questionnaire sent by the team that operated, or a register checked a year or two after treatment.

The statistics that are often cited concerning detransition are sourced from gender clinics, and only people who reported their detransition to the gender clinics are "counted" in the census. Since the grand majority of detransitioners do not report their detransitions to their clinics, there is no legitimate statistic on the actual rate of detransition. —-ph-7-, detrans

The studies that show a 1-2% detransition rate were done before the informed consent model was implemented, when psychological assessments were required. So there is no evidence to support us being rare, or not rare. —Weird-Experience-123, detrans

That second point matters. The adult cohorts behind the classic low figures were mostly males assessed under strict, slow protocols, often for years. Today's referrals are mostly adolescent and young adult females, often with other mental health conditions, and many receive hormones under faster, consent-based models (Irwig 2022; see demographic shift). Even a perfectly accurate figure from one group would not transfer to the other.

Where the two views meet

Both sides are partly right about the other's numbers. The trans critique of broad definitions is correct: a 30% prescription gap is not a 30% detransition rate. The detransitioner critique of clinic and survey designs is also correct: a clinic that never hears about detransition, or a survey that only asks trans people, cannot produce a low rate that means what it is taken to mean. What neither side can honestly say is that the true rate is known.

What a reliable estimate would need

Reviewers and critics broadly agree on what is needed (Cohn 2023; Feigerlova 2025; MacKinnon et al. 2023): a group defined by the treatment received rather than current identity; five to ten years of follow-up; low, separately reported loss to follow-up; shared definitions that separate discontinuation, detransition and regret; linked national registers, as in Finland and Sweden; and a way to report detransition without returning to the clinic that treated you.

Until studies like this exist, the best available summary is a range of minimums and sample descriptions: roughly 1% to 8% detransition or discontinuation in most clinic and register data within a few years, about 30% stopping hormones in one insurance cohort, rising risk in more recent Finnish cohorts, and long delays that most studies have not yet waited out. Patients deciding about medical transition deserve to hear that range, and that the true figure is unknown, as part of informed consent.

References
  • Bachmann, C. J. et al. (2024). Gender Identity Disorders Among Young People in Germany: Prevalence and Trends, 2013–2022. Deutsches Ärzteblatt International. study page, source.
  • Boskey, E. R. et al. (2025). A Retrospective Cohort Study of Transgender Adolescents Gender-Affirming Hormone Discontinuation. Journal of Adolescent Health. study page, source.
  • Boyd, I., Hackett, T. & Bewley, S. (2022). Care of Transgender Patients: A General Practice Quality Improvement Approach. Healthcare. study page, source.
  • Brik, T. et al. (2020). Trajectories of Adolescents Treated with Gonadotropin-Releasing Hormone Analogues for Gender Dysphoria. Archives of Sexual Behavior. study page, source.
  • Bruce, L. et al. (2023). Long-Term Regret and Satisfaction With Decision Following Gender-Affirming Mastectomy. JAMA Surgery. study page, source.
  • Bustos, V. P. et al. (2021). Regret after Gender-affirmation Surgery: A Systematic Review and Meta-analysis of Prevalence. Plastic and Reconstructive Surgery Global Open. study page, source.
  • Butler, G. et al. (2022). Discharge outcome analysis of 1089 transgender young people referred to paediatric endocrine clinics in England 2008–2021. Archives of Disease in Childhood, 107(11), 1018–1022. source.
  • Carmichael, P. et al. (2021). Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK. PLOS ONE. study page, source.
  • Clark, K. D. et al. (2025). Stability After Legal Gender Change Among Adults With Gender Dysphoria. JAMA Network Open. study page, source.
  • Cohn, J. (2023). The Detransition Rate Is Unknown. Archives of Sexual Behavior. study page, source (includes the description of Davies, McIntyre & Rypma 2019, an EPATH conference abstract).
  • de Vries, A. L. C. et al. (2011). Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. Journal of Sexual Medicine. study page, source.
  • Dhejne, C. et al. (2014). An analysis of all applications for sex reassignment surgery in Sweden, 1960–2010: prevalence, incidence, and regrets. Archives of Sexual Behavior. study page, source.
  • Feigerlova, E. (2025). Prevalence of detransition in persons seeking gender-affirming hormonal treatments: a systematic review. Journal of Sexual Medicine. study page, source.
  • Hall, R., Mitchell, L. & Sachdeva, J. (2021). Access to care and frequency of detransition among a cohort discharged by a UK national adult gender identity clinic: retrospective case-note review. BJPsych Open. study page, source.
  • Irwig, M. S. (2022). Detransition Among Transgender and Gender-Diverse People—An Increasing and Increasingly Complex Phenomenon. Journal of Clinical Endocrinology & Metabolism. study page, source.
  • James, S. E. et al. (2016). The Report of the 2015 U.S. Transgender Survey. National Center for Transgender Equality. source.
  • Kaltiala, R., Helminen, M., Holttinen, T. & Tuisku, K. (2024). Discontinuing hormonal gender reassignment: a nationwide register study. BMC Psychiatry, 24, 566. source.
  • Kettula, K. et al. (2025). Gender Dysphoria and Detransitioning in Adults: An Analysis of Nine Patients from a Gender Identity Clinic from Finland. Archives of Sexual Behavior. study page, source.
  • Littman, L. (2021). Individuals Treated for Gender Dysphoria with Medical and/or Surgical Transition Who Subsequently Detransitioned: A Survey of 100 Detransitioners. Archives of Sexual Behavior. study page, source.
  • Littman, L., O'Malley, S., Kerschner, H. & Bailey, J. M. (2024). Detransition and Desistance Among Previously Trans-Identified Young Adults. Archives of Sexual Behavior. study page, source.
  • MacKinnon, K. R. et al. (2022). Health Care Experiences of Patients Discontinuing or Reversing Prior Gender-Affirming Treatments. JAMA Network Open. study page, source.
  • MacKinnon, K. R., Expósito-Campos, P. & Gould, W. A. (2023). Detransition needs further understanding, not controversy. BMJ. study page, source.
  • MacKinnon, K. R. et al. (2025). A Latent Class Analysis of Interrupted Gender Transitions and Detransitions in the USA and Canada (DARE study). Archives of Sexual Behavior. source, summary.
  • Narayan, S. K. et al. (2021). Guiding the conversation—types of regret after gender-affirming surgery and their associated etiologies. Annals of Translational Medicine. study page, source.
  • Nyquist, C. B. et al. (2025, retracted 2026). Treatment trajectories among children and adolescents referred to the Norwegian National Center for Gender Incongruence. Acta Paediatrica. study page, source.
  • Rackliff, L. et al. (2025). "Providers had no idea what to do with me": A mixed-methods analysis of detransition/retransition support, care, and information needs among sexual and gender minority individuals. International Journal of Transgender Health. study page, source.
  • Rastogi, A. et al. (2025). Health and Wellbeing: Findings from the 2022 U.S. Trans Survey. Advocates for Trans Equality. source.
  • Roberts, C. M. et al. (2022). Continuation of Gender-affirming Hormones Among Transgender Adolescents and Adults. Journal of Clinical Endocrinology & Metabolism. study page, source.
  • Tang, A. et al. (2022). Gender-Affirming Mastectomy Trends and Surgical Outcomes in Adolescents. Annals of Plastic Surgery. study page, source.
  • Turban, J. L. et al. (2021). Factors Leading to "Detransition" Among Transgender and Gender Diverse People in the United States: A Mixed-Methods Analysis. LGBT Health. study page, source.
  • van der Loos, M. A. T. C. et al. (2022). Continuation of gender-affirming hormones in transgender people starting puberty suppression in adolescence: a cohort study in the Netherlands. Lancet Child & Adolescent Health. study page, source.
  • Vandenbussche, E. (2022). Detransition-Related Needs and Support: A Cross-Sectional Online Survey. Journal of Homosexuality. study page, source.
  • Wiepjes, C. M. et al. (2018). The Amsterdam Cohort of Gender Dysphoria Study (1972–2015): Trends in Prevalence, Treatment, and Regrets. Journal of Sexual Medicine. study page, source.

Last updated: · 1 view

Suggest an Article or an Improvement

Spotted something missing, unclear or wrong on this page, or have an idea for a related article? Let us know and we'll take a look.

Only if you'd like a reply

Related pages: